C.M. Bidwell & Associates’s PhenomeX Inc. Common Stock CELL Stock Holding History

C.M. Bidwell & Associates’s Portfolio CELL Stock Details CELL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-916	Closed	-$914	–	590
2023 Q3	$914	Hold	916	–	–	﹤0.01%	504
2023 Q2	$449	Hold	916	–	–	﹤0.01%	499
2023 Q1	$1.06K	Hold	916	–	–	﹤0.01%	494
2022 Q4	$2.46K	Buy	+916	New	+$2.42K	﹤0.01%	424
2022 Q3	–	Sell	-150	Closed	-$1K	–	560
2022 Q2	$1K	Hold	150	–	–	﹤0.01%	483
2022 Q1	$1K	Buy	+150	New	+$1.24K	﹤0.01%	524

C.M. Bidwell & Associates's CELL Position: Q4 2023 in Review

C.M. Bidwell & Associates sold out of PhenomeX Inc. Common Stock (CELL) in Q4 2023, closing a stake of 916 shares — an estimated $914 sold.

C.M. Bidwell & Associates first reported a position in CELL in Q1 2022 and held it in 6 quarters. The position peaked at $2.46K in Q4 2022. 0 funds tracked by Wall St. Rank hold CELL as of Q4 2023.

C.M. Bidwell & Associates reported no remaining PhenomeX Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 916 PhenomeX Inc. Common Stock shares in Q4 2023, an estimated $914.
C.M. Bidwell & Associates first reported a position in PhenomeX Inc. Common Stock in Q1 2022 and held it in 6 quarters.
C.M. Bidwell & Associates's PhenomeX Inc. Common Stock position peaked at $2.46K in Q4 2022.
0 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q4 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2023, filed 14 Feb 2024.